Clinical trial · Interventional
Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells
A Pilot Trial of Unrelated Umbilical Cord Blood Transplantation Augmented With Ex Vivo CytokinePrimed ALDHbr Umbilical Cord Blood Cells
NCT00692926CI-TRIAL-00028329completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main purpose of this investigational (not approved by the FDA) Phase I research is to test whether transplantation of umbilical cord blood cells can be safely supplemented with a transfusion of a portion of these cells that have been sorted (collected from a special machine called a cell sorter) and then either infused a few hours after the standard transplant or for some patients grown in a special system in the laboratory prior to the transplant, designed to increase the number of stem cells transplanted. This system is currently in the early phases of testing.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia, Aplastic | — | UNRESOLVED | — |
| Congenital Immunodeficiency Syndrome | — | UNRESOLVED | — |
| Congenital Marrow Failure | — | UNRESOLVED | — |
| Inborn Errors of Metabolism | — | UNRESOLVED | — |
| MDS | Myelodysplastic Syndrome | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ALDHbr Umbilical Cord Blood Cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- OTHER
- label
- 20% primed UCB
- description
- 20% of UCB is ALDHbr sorted and primed and give on transplant day after conventional graft
- interventionNames
- Biological: ALDHbr Umbilical Cord Blood Cells
- type
- OTHER
- label
- 20% un-primed
- description
- 20% of UCB is ALDHbr freshly sorted and give on transplant day 4-8 hrs after conventional graft
- interventionNames
- Biological: ALDHbr Umbilical Cord Blood Cells
- type
- OTHER
- label
- Double- 1 unit primed
- description
- patient receives 1 conventional UCB unit and 1 unit that has been ALDHbr sorted and primed
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 55 Years
Show eligibility criteria text
Inclusion Criteria: -Hematologic Malignancy: High risk ALL in first complete remission ALL or ANLL in second or subsequent remission ANLL in relapse MDS CML in any chronic phase or accelerated phase Severe aplastic anemia refractory to medical therapy The subject is negative for CNS disease at time of enrollment. * Inborn errors of metabolism Hurler Syndrome (MPS I) Hurler-Scheie Syndrome Hunter Syndrome (MPS II) Sanfilippo Syndrome (MPS III) Morquio Syndrome (MPS IV) Maroteaux-Lamy Syndrome (MPS VI) Krabbe Disease (Globoid Leukodystrophy) Metachromatic Leukodystrophy (MLD) Adrenoleukodystrophy(ALD and AMN) Sandhoff Disease Tay Sachs Disease The subject does NOT have uncontrolled seizures, apnea, evidence of aspiration pneumonia or evidence of brain stem involvement on MRI scans * Congenital marrow failure Amegakaryocytic thrombocytopenia TAR Kostmann's Syndrome Schwachman-Diamond Syndrome Blackfan-Diamond Anemia * Congenital immunodeficiency syndromes requiring myeloablative therapy Wiscott Aldrich Syndrome LAD CGD FEL/HLH CVID/CID * SUBJECT'S DONOR Subject does NOT have a 6/6 or 5/6 antigen matched related bone marrow donor. Suitably matched cord blood unit with adequate cell dose is available. Unit must be in a dual compartment bag. PERFORMANCE STATUS and ORGAN FUNCTION * \<55 years of age at time of enrollment. * Lansky score between 60% and 100%, or a Karnofsky score between 50% and 100% * Adequate function of other organ systems * Creatinine \< 2.0 mg/dl and creatinine clearance \> 50 cc/min/m2 * Hepatic transaminases (ALT/AST) \< 4 x normal, bilirubin \< 2.0 mg/dl * Normal cardiac function by echocardiogram or radionuclide scan * Pulmonary function tests demonstrating FVC, CVC, and FEV1 of \>60% of predicted for age. For adult patients DLCO \> 60% of predicted. If patient cannot perform PFTs, clearance by the pediatric or adult pulmonologist will be required * No uncontrolled infections at the time of cytoreduction * NOT pregnant or lactating (must have a current negative pregnancy test) * HIV negative * Subject is not concurrently involved in any other clinical trial that affects engraftment or immune reconstitution (e.g. other hematopoietic growth factors). * Subject does not have any co-morbid condition, which in the view of the Principal Investigators, renders the patient at too high a risk from treatment complications and regimen related morbidity/mortality.
References
Publications (0)
Data not yet available
No reference posted for this study.